HPM Partners LLC raised its position in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 4.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 11,958 shares of the medical equipment provider’s stock after acquiring an additional 484 shares during the quarter. HPM Partners LLC’s holdings in Zimmer Biomet were worth $1,443,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently made changes to their positions in ZBH. Wells Fargo & Company MN increased its stake in shares of Zimmer Biomet by 98.8% during the fourth quarter. Wells Fargo & Company MN now owns 2,044,375 shares of the medical equipment provider’s stock valued at $246,695,000 after acquiring an additional 1,016,085 shares during the period. Alyeska Investment Group L.P. increased its stake in shares of Zimmer Biomet by 249.3% during the third quarter. Alyeska Investment Group L.P. now owns 1,019,872 shares of the medical equipment provider’s stock valued at $119,417,000 after acquiring an additional 727,925 shares during the period. Jana Partners LLC increased its stake in shares of Zimmer Biomet by 16.6% during the third quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock valued at $545,932,000 after acquiring an additional 662,497 shares during the period. American Century Companies Inc. increased its stake in shares of Zimmer Biomet by 14.7% during the fourth quarter. American Century Companies Inc. now owns 4,777,397 shares of the medical equipment provider’s stock valued at $576,488,000 after acquiring an additional 612,044 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Zimmer Biomet by 24.4% during the third quarter. Bank of New York Mellon Corp now owns 2,759,704 shares of the medical equipment provider’s stock valued at $323,134,000 after acquiring an additional 541,102 shares during the period. Institutional investors own 86.64% of the company’s stock.
In other news, insider Bryan C. Hanson acquired 25,077 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The stock was purchased at an average price of $119.68 per share, with a total value of $3,001,215.36. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Chad F. Phipps sold 20,826 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $115.95, for a total transaction of $2,414,774.70. The disclosure for this sale can be found here. Company insiders own 1.07% of the company’s stock.
Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.10. The firm had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.03 billion. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.14 earnings per share. equities analysts forecast that Zimmer Biomet Holdings Inc will post 7.8 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.81%. Zimmer Biomet’s dividend payout ratio is 10.65%.
A number of research analysts recently commented on ZBH shares. Morgan Stanley raised their price objective on shares of Zimmer Biomet from $140.00 to $150.00 in a research note on Monday, January 29th. ValuEngine upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Thursday, January 11th. SunTrust Banks raised their price objective on shares of Zimmer Biomet to $142.00 and gave the company a “buy” rating in a research note on Monday, January 29th. Deutsche Bank upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price objective on the stock in a research note on Tuesday, November 14th. Finally, Oppenheimer reiterated a “buy” rating on shares of Zimmer Biomet in a research note on Tuesday, December 19th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Zimmer Biomet presently has a consensus rating of “Buy” and a consensus target price of $141.06.
COPYRIGHT VIOLATION NOTICE: “HPM Partners LLC Has $1.44 Million Holdings in Zimmer Biomet Holdings Inc (ZBH)” was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/03/13/hpm-partners-llc-has-1-44-million-holdings-in-zimmer-biomet-holdings-inc-zbh.html.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.